Pyxis Oncology, Inc. business relationships
Companies named in Pyxis Oncology, Inc.’s 10-K filed 2026-03-23, and public companies whose annual reports name Pyxis Oncology, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- <1 / 100 Top 6% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Pyxis Oncology, Inc.’s annual report 6
“Cost of revenues in each period consisted of the write-off of the remaining carrying value of the definite-lived intangible asset associated with royalty rights sold to Simcere pursuant to the Simcere Agreement in 2025 and to Novartis pursuant to the Settlement Agreement in 2024.” SEC filing
“Other than already approved programs (i.e. Simcere's Enzeshu®, Novartis' Beovu®) there is no guarantee that any of the other product candidates discovered using our APXiMAB Platform, whether developed by us or our licensees, will receive regulatory approval.” SEC filing
“The initial licensed targets include CD123 and EDB+FN and the Company has the option to expand the scope of its license to add additional licensed targets that have not been licensed to a third party or are not the subject of a Pfizer ADC development program.” SEC filing
“Our MICVO product candidate was built utilizing the FACT Platform, initially licensed from Pfizer in December 2020, before securing an exclusive license to the FACT Platform in October 2022.” SEC filing
“The agreement does not provide Merck with any rights to MICVO outside of the collaboration study.” SEC filing
“In November 2024, we announced a Clinical Trial Collaboration and Supply Agreement with Merck & Co, Inc. or Merck (known as MSD outside of the United States and Canada), for a Pyxis Oncology-sponsored study of MICVO in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.